An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: a drug repositioning
This allows assessment of how much improvement persists after the peptide clears the system
PMID: 40756949
Metabolic and Bariatric Surgery (MBS) Source: Barrett, et al JAMA Surgery, September 17, 2025 Implications for employers: Bariatric surgery costs less than GLP-1 medications, and is likely more effective at inducing weight loss than older GLP-1 agents, which are not usually used for weight loss at this point
GLP-1 RAs mimic this effect by enhancing glucose-dependent insulin secretion, inhibiting glucagon, delaying gastric emptying, and reducing appetite mechanisms that can improve glycemic control and support weight loss [1]
The innovation model is additive (i.e., layer benefits onto familiar formats)